Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
- Korean prostate cancer over 50 years old with pathological confirmation
- Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination
within 6 months since starting.
- Patients measured bone density level before starting to receive hormone therapies
- Patients who are treated other anti-osteoporosis drugs and who are treated
bisphosphate due to BMD T score below -3.0.
- Patients who are hard to be analysed by attach to other bone disease.
- Patients who are hard to be analysed by limitation of chart record according to
Type of Study:
Observational Model: Case-Only, Time Perspective: Prospective
comparison of bone density before and after hormone therapy
Outcome Time Frame:
Joon Woo Bahn
Korea: Food and Drug Administration
- GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients
- bone mineral loss
- prostate cancer
- GnRH agonist alone vs. GnRH agonist plus anti-androgen combination
- Prostatic Neoplasms